Lipocine Inc. filed a Form 8-K on November 10, 2026, disclosing that the company dosed the first participant in its BLOOM Phase 3 Study of LPCN 1154 for postpartum depression.

Key Highlights

  • First participant dosed: Lipocine announced the dosing of the first participant in its BLOOM Phase 3 Study of LPCN 1154 for postpartum depression on November 10, 2026.
  • Compound studied: The investigational compound is LPCN 1154, being evaluated for the treatment of postpartum depression.
  • Study name: The clinical trial is designated the BLOOM Phase 3 Study, according to the filing.
  • Disclosure vehicle: The announcement was made via a press release furnished as Exhibit 99.1 to the report.
  • Signing officer: The report was signed by Mahesh V. Patel, President and Chief Executive Officer of Lipocine Inc.

Lipocine Initiates BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression

Lipocine Inc. (NASDAQ:LPCN), a Delaware-incorporated pharmaceutical company headquartered at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108, reported on November 10, 2026, that it had dosed the first participant in its BLOOM Phase 3 Study. The study is evaluating LPCN 1154 as a treatment for postpartum depression, according to the filing submitted under Item 8.01 (Other Events) of Form 8-K.

The company disclosed that the milestone announcement was communicated through a press release, a copy of which was furnished as Exhibit 99.1 to the current report. The filing incorporated the press release by reference. No financial data, trial design details, enrollment targets, or timeline projections were included in the body of the 8-K itself; those disclosures, if any, would reside in the exhibit.

The report was signed on November 10, 2026, by Mahesh V. Patel in his capacity as President and Chief Executive Officer of Lipocine Inc. The company's Commission File Number is 001-36357, and its common stock carries a par value of $0.0001 per share. Lipocine indicated it is not an emerging growth company.

What Was Disclosed

Lipocine Inc. filed an 8-K on November 10, 2026, to report that the first participant had been dosed in the BLOOM Phase 3 Study of LPCN 1154 for postpartum depression, with a press release furnished as Exhibit 99.1.